The aim of this WG is to identify the epidemiological heterogeneity and natural course of BTC in Europe to define a strategy of precision prevention based on the prevalence of risks factors, molecular traits, and genomic features.
Working Groups
Vincenzo Cardinale
WG1 Leader
Martin Cornillet
WG1 co-Leader
Marcin Krawczyk
WG1 co-Leader
Identification of epidemiological heterogeneity in Europe to apply precision prevention
Tasks & Activities
Creation of a digital interconnected platform for multiple data sharing.
Delineating differences in the risk factors for each type of BTC.
Exploring regional differences in incidence, mortality, and access to molecular classification/treatments across European countries.
Establishing correct and consistent practice regarding the diagnosis, classification, and coding of BTC based on the new International Classification of Diseases 11th Revision (ICD-11 and ICD-O5).
Exploring histo-morphology and molecular traits of populations at risk to personalize the definition of risk of cancer development.
Exploring the genomic features of PSC-, cirrhosis- and biliary tract stone disease-associated BTC to identify a personalised tumour risk and management.
Exploring preventive measures in at-risk populations (e.g., aspirin, statins, metformin).
Identify age of onset of mutational profile from start of inflammatory stimulus for the development of a personalised prevention strategy.